Cinemark Holdings, Inc. (CNK): debt financing — Cinemark cuts revolver rate by 1.50% and upsizes facility by $100M to $225M

Cinemark Holdings, Inc.

Revolving loan interest rate reduced by 1.50%; initial Level 2 pricing set at 1.75% Term Benchmark and 0.75% ABR.
Revolving commitments increased by $100 million to a total of $225 million.
Maturity remains May 26, 2028, with springing date of April 15, 2028.
Commitment fee on unused portion ranges from 0.25% to 0.375%, payable quarterly.
Texas Capital Bank added as a Revolving Lender and Issuing Bank.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Cinemark Holdings, Inc. amended revolving credit of $100,000,000 (to a total aggregate commitment of revolving loans equal to $225,000,000) with Barclays Bank PLC at reduce the rate at which the revolving loans bear interest by 1.50% maturing May 26, 2028.

Instrument: revolving credit
Principal: $100,000,000 (to a total aggregate commitment of revolving loans equal to $225,000,000)
Counterparty: Barclays Bank PLC
Rate: reduce the rate at which the revolving loans bear interest by 1.50%
Maturity: May 26, 2028
Event: amendment

Exact text from the filing

things, reduce the rate at which the revolving loans bear interest by 1.50% and increase the aggregate commitment of the revolving loans available to us by an amount equal to $100,000,000 (to a total aggregate commitment of revolving loans equal to $225,000,000). The revolving credit facility is scheduled to mature on May 26, 2028, subject to a springing maturity

View on SEC.gov

309 debt financings filed in the last 30 days. Browse all debt financings →

Cinemark Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-197288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.